Skip to main content

$0.040 0.004 (11.11%)

High

$0.04

Low

$0.04

Trades

37

Turnover

$81,892

Volume

2,106,389
30 June 2023 at 3:45pm
Register to track NTI and receive email alerts.
Subject
NTI Ann: Notification of cessation of securities - NTI

NTI Ann: Notification regarding unquoted securities - NTI

NTI Ann: NTI to Present at Rett Syndrome Foundation Meeting

NTI Ann: Results of Meeting

NTI Ann: NTI Granted 2 Year Extension of Treatment for ASD Patients

NTI Ann: NTI granted HREC Approval for PANDAS/PANS Trial Extension

NTI Ann: Notification of cessation of securities - NTI

NTI Ann: NTI Completes Recruitment in PANDAS/PANS Clinical Trial

NTI Ann: Proposed issue of securities - NTI

NTI Ann: Notification of cessation of securities - NTI

NTI Ann: Notice of General Meeting/Proxy Form

NTI Ann: Quarterly Activities/Appendix 4C Cash Flow Report

NTI Ann: Notice of Quarterly Investor Conference Call

NTI Ann: Neurotech to Present at NWR Virtual Healthcare Conference

NTI Ann: Investor Presentation

NTI Ann: NTI to Launch Phase II Clinical Trial in Rett Syndrome

NTI Ann: Investor Conference Call - 52 Week Autism Study Results

NTI Ann: Investor Presentation

NTI Ann: Phase I/II ASD Clinical Trials Results at 52 Weeks

NTI Ann: Trading Halt

NTI Ann: Notification of cessation of securities - NTI

NTI Ann: Notification regarding unquoted securities - NTI

NTI Ann: Appendix 4D and Half Year Accounts

NTI Ann: First Patient Treated in Phase I/II PANDAS/PANS Trial

NTI Ann: Approval for Additional Phase I/II ASD Trial Extension

NTI Ann: Secondary Trading Notice

NTI Ann: Application for quotation of securities - NTI

NTI Ann: Top 20 securityholders

NTI Ann: Distribution Schedule

NTI Ann: Application for quotation of securities - NTI

NTI Ann: Quarterly Activities/Appendix 4C Cash Flow Report

NTI Ann: HREC Approval for Phase I/II PANDAS/PANS Clinical Trial

NTI Ann: Secondary Trading Notice

NTI Ann: Application for quotation of securities - NTI

NTI Ann: Notice of Quarterly Investor Conference Call

NTI Ann: NTI Granted FDA Pre-IND Meeting for NTI164 in ASD

NTI Ann: Extension of Offers under Prospectus

NTI Ann: Change of Director's Interest Notice x2

NTI Ann: Notification regarding unquoted securities - NTI

NTI Ann: Application for quotation of securities - NTI

NTI Ann: Proposed issue of securities - NTI

NTI Ann: Target Market Determination - Option Offer

NTI Ann: Disclosure Document

NTI Ann: Application for quotation of securities - NTI

NTI Ann: Final Director's Interest Notice

NTI Ann: Passing of a Director

NTI Ann: Commencement of Phase II/III ASD Clinical Trial

NTI Ann: Results of Meeting

NTI Ann: 2022 Annual General Meeting Presentation

NTI Ann: Chairman Address to 2022 Annual General Meeting

Register to track NTI and receive email alerts.

Similar Companies

AT1
COH
CSX
CYC
EMV
IBX
IPD
MX1
RSH
SOM